Atika Capital Management’s Cymabay Therapeutics CBAY Stock Holding History

Atika Capital Management’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-145,000	Closed	-$3.42M	–	116
2023 Q4	$3.42M	Buy	145,000 +29,000	+25%	+$516K	0.46%	64
2023 Q3	$1.73M	Buy	+116,000	New	+$1.54M	0.23%	70

Other funds holding CBAY

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Atika Capital Management's CBAY Position: Q1 2024 in Review

Atika Capital Management sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 145,000 shares — an estimated $3.42M sold.

Atika Capital Management first reported a position in CBAY in Q3 2023 and held it in 2 quarters. The position peaked at $3.42M in Q4 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.

Atika Capital Management reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
Atika Capital Management sold 145,000 Cymabay Therapeutics shares in Q1 2024, an estimated $3.42M.
Atika Capital Management first reported a position in Cymabay Therapeutics in Q3 2023 and held it in 2 quarters.
Atika Capital Management's Cymabay Therapeutics position peaked at $3.42M in Q4 2023.
1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.

Based on Atika Capital Management's 13F filing for Q1 2024, filed 14 May 2024.